Suscribirse

Modified technique of percutaneous pulmonary valve implantation with the Sapien 3: Impact on procedure and early outcome - 14/08/21

Doi : 10.1016/j.acvdsp.2021.06.073 
Ali Houeijeh, MD, PhD 1, 2, 3, , Clément Batteux, MD 1, Emre Belli, MD 1, Clément Karsenty, MD 4, Jérôme Petit, MD 1, Sébastien Hascoët, MD, PhD 1
1 Hôpital Marie-Lannelongue, groupe hospitalier Paris Saint-Joseph, centre de référence cardiopathies congénitales complexes (M3C), université Paris-Saclay, Le Plessis-Robinson, France 
2 Pediatric cardiology unit, Lille university hospital, Lille II university, Lille, France 
3 Laboratoire EA4489, Lille II university, Lille, France 
4 Cardiologie pédiatrique et congénitale, université de Toulouse, hôpital des Enfants, CHU de Toulouse, 31300 Toulouse, France 

Corresponding author. CHRU Lille, service de cardiologie pédiatrique, rue Pr.-Leclerc, 59000 Lille.CHRU Lille, service de cardiologie pédiatriquerue Pr.-LeclercLille59000

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Resumen

Introduction

Percutaneous pulmonary valve implantation (PPVI) with Sapien 3 valve is effective to treat right ventricle outflow (RVOT) dysfunction. Issues related to presenting and tricuspid valve injuries were reported with the initial implantation method. A modified technique was developed without pre-stenting and with a protective delivery method for valve implantation.

Methods

We aimed to compare procedural results in the modified technique group (MTG) to matched patients in a conventional technique group (CTG). All consecutive procedures performed in the MTG over 9months were matched based on RVOT type and size to consecutive procedures performed before.

Results

Twenty-seven patients were included in each group. Size of the Sapien 3 valves were 23mm (n=9), 26mm (n=9), 29mm (n=36). The two groups were similar regarding demographic data, RVOT type, pre-procedure hemodynamics (Table 1). PPVI was performed in a single procedure in all patients of the MTG, whereas six (22.2%) patients of the CTG group had pre-stenting as a first step and valve implantation later (P=0.02). Procedures were successful in all cases. Stent embolization was reported in two patients (7.4%) in the CTG, which were impacted in pulmonary arteries. Instability of a valve was observed in one case (3.7%) in the MTG, stabilized with two stents and an additional valve-in-valve implantation. Hemodynamics results were good in all cases without significant difference among the two groups (Table 2).

Procedure duration and fluoroscopy times were significantly reduced in the MTG (48.1 versus 82.6minutes, P<0.0001; 15.2 versus 29.8minutes, P=0.0002).

During follow-up, no stent fracture or valve dysfunction was noticed in both groups.

Conclusion

PPVI without pre-stenting and with a protective delivery method of the Sapien 3 valve reduces significantly the procedure complexity, procedure duration and irradiation, while maintaining excellent hemodynamics results.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2021  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 13 - N° 4

P. 315-316 - septembre 2021 Regresar al número
Artículo precedente Artículo precedente
  • Total cavopulmonary connection procedure in adults: A review of the medical literature
  • Hichem Sakhi, Sébastien Hascoët, Emre Belli, Meriem Kara, Emmanuelle Fournier, Régine Roussin, Sarah Cohen
| Artículo siguiente Artículo siguiente
  • A false left ventricular non-compaction; Late discovery of a corrected transposition of the great vessels in a 63-year-old patient
  • F. Saadi, B. Baloul, S. Hamadouche, B.V. Tung, N. Ghanem, V. Dormagen, G. Karrillon

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.